Supernus Pharmaceuticals (SUPN) Price Target Increased to $54.00 by Analysts at B. Riley

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target upped by research analysts at B. Riley from $50.00 to $54.00 in a report released on Thursday, December 28th, MarketBeat reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. B. Riley’s target price would indicate a potential upside of 20.67% from the stock’s previous close. B. Riley also issued estimates for Supernus Pharmaceuticals’ Q3 2018 earnings at $0.57 EPS.

A number of other research analysts have also commented on the company. Zacks Investment Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 10th. FBR & Co started coverage on Supernus Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $53.00 price target for the company. Piper Jaffray Companies reaffirmed a “hold” rating and set a $45.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, September 8th. Stifel Nicolaus upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Tuesday, November 7th. Finally, Janney Montgomery Scott upgraded Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Monday, December 4th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $49.90.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at $44.75 on Thursday. Supernus Pharmaceuticals has a 52 week low of $23.10 and a 52 week high of $50.04. The firm has a market capitalization of $2,290.00, a PE ratio of 40.68 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company’s revenue for the quarter was up 41.5% on a year-over-year basis. equities analysts anticipate that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

In related news, VP Victor Vaughn sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total value of $630,600.00. Following the sale, the vice president now owns 24,344 shares in the company, valued at approximately $1,023,421.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. Vanguard Group Inc. boosted its stake in Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after purchasing an additional 984,200 shares during the last quarter. Pictet Asset Management Ltd. lifted its holdings in shares of Supernus Pharmaceuticals by 438.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock valued at $19,651,000 after buying an additional 400,083 shares during the period. Scout Investments Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 239.5% during the 3rd quarter. Scout Investments Inc. now owns 565,900 shares of the specialty pharmaceutical company’s stock valued at $22,636,000 after buying an additional 399,225 shares during the period. Janus Henderson Group PLC bought a new position in shares of Supernus Pharmaceuticals during the 3rd quarter valued at $10,646,000. Finally, Royal Bank of Canada lifted its holdings in shares of Supernus Pharmaceuticals by 790.8% during the 2nd quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock valued at $11,699,000 after buying an additional 240,978 shares during the period. Institutional investors and hedge funds own 98.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://stocknewstimes.com/2018/01/12/supernus-pharmaceuticals-supn-price-target-raised-to-54-00-at-b-riley-2.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply